San Luis Wealth Advisors LLC Takes Position in Cencora, Inc. (NYSE:COR)

San Luis Wealth Advisors LLC acquired a new stake in shares of Cencora, Inc. (NYSE:COR - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,245 shares of the company's stock, valued at approximately $624,000.

Several other institutional investors have also recently made changes to their positions in the stock. Vista Investment Partners LLC raised its holdings in shares of Cencora by 0.3% during the first quarter. Vista Investment Partners LLC now owns 19,754 shares of the company's stock valued at $5,493,000 after purchasing an additional 61 shares during the period. Louisbourg Investments Inc. raised its holdings in shares of Cencora by 23.0% in the 1st quarter. Louisbourg Investments Inc. now owns 600 shares of the company's stock worth $167,000 after acquiring an additional 112 shares during the last quarter. Grove Bank & Trust raised its holdings in shares of Cencora by 695.3% in the 1st quarter. Grove Bank & Trust now owns 843 shares of the company's stock worth $234,000 after acquiring an additional 737 shares during the last quarter. QRG Capital Management Inc. raised its holdings in shares of Cencora by 0.4% in the 1st quarter. QRG Capital Management Inc. now owns 20,215 shares of the company's stock worth $5,622,000 after acquiring an additional 73 shares during the last quarter. Finally, Sagespring Wealth Partners LLC raised its holdings in shares of Cencora by 14.5% in the 1st quarter. Sagespring Wealth Partners LLC now owns 1,908 shares of the company's stock worth $531,000 after acquiring an additional 242 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company's stock.

Cencora Stock Down 1.1%

Cencora stock opened at $292.38 on Tuesday. Cencora, Inc. has a 1-year low of $218.65 and a 1-year high of $309.35. The firm has a market capitalization of $56.67 billion, a price-to-earnings ratio of 41.59, a P/E/G ratio of 1.31 and a beta of 0.58. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. The firm has a 50 day simple moving average of $287.60 and a 200 day simple moving average of $262.11.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $4.42 EPS for the quarter, beating the consensus estimate of $4.07 by $0.35. Cencora had a net margin of 0.46% and a return on equity of 328.62%. The firm had revenue of $75.50 billion during the quarter, compared to the consensus estimate of $75.41 billion. During the same period last year, the firm earned $3.80 EPS. The business's quarterly revenue was up 10.3% compared to the same quarter last year. On average, analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, June 2nd. Stockholders of record on Friday, May 16th were paid a $0.55 dividend. The ex-dividend date of this dividend was Friday, May 16th. This represents a $2.20 annualized dividend and a dividend yield of 0.75%. Cencora's dividend payout ratio is presently 25.52%.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. Wells Fargo & Company upgraded shares of Cencora from an "equal weight" rating to an "overweight" rating and upped their target price for the stock from $274.00 to $337.00 in a report on Tuesday, June 3rd. Wall Street Zen upgraded shares of Cencora from a "hold" rating to a "buy" rating in a report on Wednesday, March 12th. Bank of America upped their target price on shares of Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a report on Friday, April 11th. Robert W. Baird increased their price objective on shares of Cencora from $314.00 to $350.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. Finally, Citigroup increased their price objective on shares of Cencora from $330.00 to $355.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. One analyst has rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, Cencora currently has a consensus rating of "Moderate Buy" and an average target price of $306.91.

Insider Transactions at Cencora

In related news, EVP Elizabeth S. Campbell sold 4,127 shares of the stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $268.28, for a total transaction of $1,107,191.56. Following the transaction, the executive vice president now owns 14,665 shares in the company, valued at $3,934,326.20. This represents a 21.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Robert P. Mauch sold 4,969 shares of the stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $289.33, for a total transaction of $1,437,680.77. Following the transaction, the chief executive officer now owns 47,582 shares in the company, valued at approximately $13,766,900.06. This trade represents a 9.46% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 38,253 shares of company stock worth $10,582,297. Corporate insiders own 10.80% of the company's stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.